Tocagen Presents Interim Data from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology (SNO)
Exciting reports from the SNO meeting! Highlight is almost a doubling of survival time for patients using Toca511 compared to historical controls. These were small uncontrolled trials but they show enough promise that they justify a large phase 2/3 trial which is starting right now!
(disclaimer: Tocagen is a sponsor of our organization)
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://www.tocagen.com/investor-relations/press-release/tocagen-presents-interim-data-from-studies/
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines